NasdaqGS:GILDBiotechs
Gilead Sciences (GILD) Valuation Check After Oncology And HIV Therapy Momentum
Gilead Sciences (GILD) has returned to focus after a series of company-specific catalysts, including its oncology expansion through Repare Therapeutics, FDA approval of HIV prevention drug Yeztugo, and encouraging updates for Trodelvy and Yescarta.
See our latest analysis for Gilead Sciences.
These company specific catalysts have coincided with a sharp shift in market sentiment, with a 30 day share price return of 23.1% and a 1 year total shareholder return of 56.6% suggesting momentum has...